Merck & Co. (MRK) EVP Chirfi Guindo sells 10,000 common shares

Rhea-AI Filing Summary

Merck & Co., Inc. executive Chirfi Guindo, EVP, Access, Policy & Comms, reported selling 10,000 shares of common stock on August 13, 2026 in a sale classified as an open market or private transaction at $135.00 per share. Following this transaction, Guindo directly holds 36,613.127 shares of Merck common stock.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Guindo Chirfi

Role EVP, Access, Policy & Comms

Sold 10,000 shs ($1.35M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$135.00	$1.35M

Holdings After Transaction: Common Stock — 36,613.127 shares (Direct)

Key Figures

Shares sold: 10,000 shares Sale price per share: $135.00 per share Shares owned after transaction: 36,613.127 shares +2 more

5 metrics

Shares sold 10,000 shares Common stock sold on August 13, 2026

Sale price per share $135.00 per share Price for the 10,000 Merck common shares sold

Shares owned after transaction 36,613.127 shares Direct Merck common stock holdings following the sale

Sell transactions reported 1 Single sale transaction in this Form 4

Net shares sold 10,000 shares Net change in position from reported transactions

Key Terms

Sale in open market or private transaction, acquired/disposed code, direct ownership

3 terms

Sale in open market or private transaction financial

"transaction code description "Sale in open market or private transaction""

acquired/disposed code financial

"The entry shows acquired_disposed_code "D" for the sale"

direct ownership financial

"The ownership_type field identifies the position as direct ownership"

FAQ

What insider transaction did Merck (MRK) report for Chirfi Guindo?

Merck reported that EVP Chirfi Guindo sold 10,000 shares of common stock on August 13, 2026. The trade was classified as a sale in an open market or private transaction at $135.00 per share.

At what price did Chirfi Guindo sell Merck (MRK) shares?

Chirfi Guindo sold Merck common stock at $135.00 per share. The Form 4 classifies the transaction as a sale in an open market or private transaction involving 10,000 shares on August 13, 2026.

How many Merck (MRK) shares does Chirfi Guindo own after the sale?

After the reported sale, Chirfi Guindo directly owns 36,613.127 shares of Merck common stock. This post-transaction holding reflects the remaining stake following the 10,000-share sale reported on August 13, 2026.

What role does Chirfi Guindo hold at Merck (MRK)?

Chirfi Guindo is reported as an officer of Merck, serving as EVP, Access, Policy & Comms. The Form 4 links this executive position to the disclosed sale of 10,000 Merck common shares.

Was the Merck (MRK) insider sale by Chirfi Guindo a buy or sell transaction?

The transaction was a sale of Merck common stock. The Form 4 shows transaction code "S" and an acquired/disposed code of "D," indicating a disposition of 10,000 shares at $135.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 05:02 PM Accepted by SEC EDGAR 08/13/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guindo Chirfi

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NEW JERSEY 07065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Access, Policy & Comms

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		S		10,000	D	$135	36,613.127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kelly Grez, as attorney-in-fact for Chirfi Guindo	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)